Novartis India Share Price
Small Cap | Pharmaceuticals and health care | BSE: 500672
₹836.00 
-0.10 (-0.01 %)
Last Updated: 21 Feb 2025 04:01 PM
BEARISH
Overview
Open (₹) 844.00
High (₹) 844.00
Low (₹) 833.00
Prev. Close (₹) 836.10
Volume 786
VWAP (₹) 837.91
ROCE (%) 16.19
Industry P/E 43.99
TTM P/E 23.93
P/B Ratio 2.77
Market Cap (₹) Cr.2,064.15
Dividend Yield (%)2.99
EPS (₹) 34.50
ROE11.43%
Sales Growth (%) -11.53
Profit Growth (%)-17.58
Day Range
844.00844.00
52 Week Range
790.351,248.00
Historical Returns
Returns (6M)
-26.54 %
Returns (1Y)
-17.93 %
Returns (3Y)
26.52 %
Returns (5Y)
35.76 %
Returns (6M)
-26.54 %
Returns (1Y)
-17.93 %
Returns (3Y)
26.52 %
Returns (5Y)
35.76 %
SWOT Analysis
Technicals
Technical Rating
BEARISHRSI 52.70
MFI 52.63
ATR 24.16
Commodity Channel Index -27.65
ROC125 -26.69
ROC21 -7.63
Williams %R -47.92
Resistance & Support
| Type | Resistance 1 | Resistance 2 | Resistance 3 | PP | Support 1 | Support 2 | Support 3 |
|---|---|---|---|---|---|---|---|
| Current | 842.34 | 848.67 | 853.34 | 837.67 | 831.34 | 826.67 | 820.34 |
| Week Ago | 829.75 | 856.85 | 872.70 | 813.90 | 786.80 | 770.95 | 743.85 |
| Month Ago | 872.74 | 889.87 | 900.74 | 861.87 | 844.74 | 833.87 | 816.74 |
EMA & SMA
836.00
Current Price
Bullish Moving Averages
9
Bearish Moving Averages
11
5 Day 811.55
9 Day 824.74
10 Day 829.64
12 Day 835.86
14 Day 837.44
20 Day 848.47
26 Day 854.43
50 Day 895.68
100 Day 979.05
200 Day 1039.86
Deals & Announcements
Bulk and Block Deals
Insider Trading
Corporate Actions
| Announcement Date | Subject | Ex - Date | Record Date |
|---|---|---|---|
| 10 May, 2024 | Rs.25.0000 per share(500%)Final Dividend | 23 Jul, 2024 | 01 Jan, 1970 |
| 11 May, 2023 | Rs.37.5000 per share(750%)Special Dividend | 20 Jul, 2023 | 01 Jan, 1970 |
| 10 May, 2023 | Rs.10.0000 per share(200%)Final Dividend | 20 Jul, 2023 | 01 Jan, 1970 |
Announcements
| Date | Source | Detail |
|---|---|---|
| 20 Feb, 2025 | BSE India | This is to inform that the Company has received order from Assistant Commissioner of CGST and Central Excise and disclosure is given pursuant to Regulation 30 read with Clause 20 Para A of Schedule III |
| 28 Jan, 2025 | BSE India | We hereby inform that the Board of Directors ('Board') of the Company at its Meeting held today i.e. January 28, 2025 inter-alia have considered and approved the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2024 as recommended by the Audit Committee of the Company. |
| 27 Dec, 2024 | BSE India | NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 ,inter alia, to consider and approve The intimation is filed to inform that the Board Meeting of the Company shall be held on Tuesday, January 28, 2025, for approval of Quarterly Financial Results for the Quarter ended as on December 31, 2024. |
| 25 Oct, 2024 | BSE India | Filing of the outcome of Board Meeting and Unaudited Financial Results for the quarter and half year ended September 30, 2024 |
| 11 Oct, 2024 | BSE India | Filing of Certificate dated 03.10.2024 under regulation 74(5) received from the Companys'' RTA for the quarter ended Sept 30, 2024 |
| 27 Sept, 2024 | BSE India | NOVARTIS INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/10/2024 ,inter alia, to consider and approve the Unaudited Financial Results for the quarter ended September 30, 2024 |
| 26 Sept, 2024 | BSE India | Filing of clarification on the email received from BSE dated September 26, 2024, on the rumor in relation to acquisition of Novartis India Limited from its Swiss Parent Company by Alkem Labs. |
| 26 Sept, 2024 | BSE India | The Exchange has sought clarification from Novartis India Ltd on September 26, 2024, with reference to news appeared in www.cnbctv18.com dated September 26, 2024 quoting \Alkem Labs in talks to acquire Novartis India from its Swiss parent\ <BR><BR>The reply is awaited. |
| 25 Sept, 2024 | BSE India | The Company Novartis India Limited has been importing DESFERAL (deforoxamine) from Novartis Pharma AG and selling it in India. This intimation is filed to inform that DESFERAL (deforoxamine) is acquired by Miten Pharma globally from Novartis Pharma AG. |
Board Meetings
| Purpose | Details | Meeting Date | Broadcast Date |
|---|---|---|---|
| Quarterly Results | -- | 28 Dec, 2024 | 28 Jan, 2025 |
| Quarterly Results | -- | 01 Oct, 2024 | 25 Oct, 2024 |
| Audited Results & Final Dividend | -- | 01 Apr, 2024 | 10 May, 2024 |
| Quarterly Results | -- | 28 Dec, 2023 | 25 Jan, 2024 |
| Quarterly Results | -- | 05 Oct, 2023 | 27 Oct, 2023 |
| Quarterly Results | -- | 03 Jul, 2023 | 26 Jul, 2023 |
| Audited Results, Final & Special Dividend | -- | 11 May, 2023 | 10 May, 2023 |
| Quarterly Results | -- | 28 Dec, 2022 | 08 Feb, 2023 |
| Quarterly Results | -- | 04 Oct, 2022 | 09 Nov, 2022 |
| Quarterly Results | -- | 01 Jul, 2022 | 27 Jul, 2022 |
Share Holding Pattern
| Owner Name | Dec, 2024 | Sept, 2024 | Jun, 2024 | Mar, 2024 | Dec, 2023 |
|---|
About Novartis India
Novartis India is a Public Limited Listed company incorporated on 13/12/1947 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24200MH1947PLC006104 and registration number is 006104. Currently Company is involved in the business activities of Wholesale of pharmaceutical and medical goods. Company’s Total Operating Revenue is Rs. 335.07 Cr. and Equity Capital is Rs. 12.34 Cr. for the Year ended 31/03/2024. Read More
Parent Organisation
Novartis AG
Founded
1947
Managing Director
-- --
NSE Symbol
--
Novartis India Management
| Name | Designation |
|---|---|
| Mr. Christopher Snook | Chairperson |
| Mrs. Shilpa Joshi | WholeTime Director & CFO |
| Mr. Falin Majmudar | Additional Whole Time Director |
| Mr. Sandra Martyres | Independent Director |
| Mr. Sanker Parameswaran | Independent Director |
| Mr. Gira Sardesai | Independent Director |
Peer Comparison
| Stocks | Market Cap | Market Price | 52 Week Low-High |
|---|---|---|---|
| SunPhrmInds | ₹4,46,576.22 | ₹1,643.75  ₹1,669.30(-1.53%) | ₹1,249.800 - ₹1,960.200 |
| Divis Labora | ₹1,56,123.40 | ₹5,757.05 ₹5,978.30(-3.70%) | ₹3,350.050 - ₹6,448.750 |
| Cipla | ₹1,21,675.13 | ₹1,475.75 ₹1,479.70(-0.27%) | ₹1,240.700 - ₹1,702.000 |
| ManKind Phar | ₹1,18,478.90 | ₹2,327.75 ₹2,348.45(-0.88%) | ₹1,910.100 - ₹3,050.000 |
| DrReddysLab | ₹1,15,939.04 | ₹1,151.80 ₹1,170.95(-1.64%) | ₹1,104.690 - ₹1,420.200 |
FAQs on Novartis India
What is the share price of Novartis India?
The share price of Novartis India on 21 Feb, 2025 is ₹ 836.00.
What is 52W high and 52W low share price of Novartis India?
The highest and lowest 52W share prices of Novartis India are ₹ 1248.000 and ₹ 745.000
What is the market cap of Novartis India?
The market capitalization of Novartis India as of 21 Feb, 2025 is ₹ 2,064.15 Crores
What is the P/E ratio of Novartis India?
The current P/E ratio of Novartis India as of 21 Feb, 2025 is 43.99
What is the PB ratio of Novartis India?
The PB ratio of Novartis India as of 21 Feb, 2025 is 2.77
Top Gainers
948IHFL26I
IBHFL NCD186
₹845.00
₹705.00 (0.20%)
GREAVESCOT
Greaves
₹281.85
₹234.90 (0.20%)
ASHSI
Ashirwd Stl
₹45.66
₹38.05 (0.20%)
CAPRO
Caprola.Chem
₹62.40
₹52.00 (0.20%)
Top Losers
DHANBANK
Dhanalak.Bnk
₹32.19
₹35.97 (-0.11%)
08MPD
08MPD
₹8.66
₹9.62 (-0.10%)
BALTE
BalurghtTran
₹27.13
₹31.24 (-0.13%)
DARSHANORNA
Darshan Orna
₹4.57
₹5.07 (-0.10%)
Market Indices
Sensex
₹78,699.07
₹78,472.48 (0.00%)